Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2

Autor: Rolando M Viani, Roger Trinh, Giuliano Rizzardini, Cristina Tural, Pierre-Marie Girard, Yiran B Hu, N. Mobashery, Hartwig H F Klinker, Linda M Fredrick, Edward Gane, Chloe Orkin, Nancy S. Shulman, David L. Wyles, Tami Pilot-Matias, Adriano Lazzarin, Jürgen K. Rockstroh, Sanjay Bhagani, Mark Nelson, Ruth Soto-Malave, Anne F Luetkemeyer

Publikováno v: Open Forum Infectious Diseases
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

Background Ombitasvir, paritaprevir with ritonavir, and dasabuvir (OBV/PTV/r ± DSV) ±ribavirin (RBV) are approved to treat hepatitis C virus (HCV) genotype 1 and 4 infection. Here, we investigate the safety and efficacy of OBV/PTV/r + DSV ±RBV for

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6961fa3ddec3fa06f99a2c4235b26e1
https://doi.org/10.1093/ofid/ofx154